Terms: = Pancreatic cancer AND PALB2, ENSG00000083093, 79728 AND Treatment
50 results:
1. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. A Somatic BRCA2-Mutated pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract] [Full Text] [Related]
3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
4. Targeting BRCA and palb2 in pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
6. The Clinical Implications of Reversions in Patients with Advanced pancreatic cancer and Pathogenic Variants in BRCA1, BRCA2, or palb2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract] [Full Text] [Related]
7. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition.
Liew SZH; Ng KW; Ishak NDB; Lee SY; Zhang Z; Chiang J; Ngeow JYY
Chin Clin Oncol; 2023 Jun; 12(3):27. PubMed ID: 37417291
[TBL] [Abstract] [Full Text] [Related]
8. Comparative Genomic Analysis of pancreatic Acinar Cell Carcinoma (PACC) and pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract] [Full Text] [Related]
9. Prevalence and Risk Factors of Germline Pathogenic Variants in pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract] [Full Text] [Related]
10. Adherence to NCCN Genetic Testing Guidelines in pancreatic cancer and Impact on treatment.
Crowley F; Gandhi S; Rudshteyn M; Sehmbhi M; Cohen DJ
Oncologist; 2023 Jun; 28(6):486-493. PubMed ID: 36933202
[TBL] [Abstract] [Full Text] [Related]
11. Platinum-Based Chemotherapy in Locally Advanced or Metastatic pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice.
Reinacher-Schick A; Arnold D; Venerito M; Goekkurt E; Kraeft AL; Seufferlein T
Oncol Res Treat; 2022; 45(12):752-763. PubMed ID: 36310006
[TBL] [Abstract] [Full Text] [Related]
12. PARPis and Other Novel, Targeted Therapeutics in pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract] [Full Text] [Related]
13. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract] [Full Text] [Related]
14. Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
Ramsey ML; Tomlinson J; Pearlman R; Abushahin L; Aeilts A; Chen HZ; Chen Y; Compton A; Elkhatib R; Geiger L; Hays J; Jeter J; Jin N; Malalur P; Roychowdhury S; Ruple J; Prebish J; Stanich PP; Hampel H
Fam Cancer; 2023 Jan; 22(1):91-97. PubMed ID: 35713757
[TBL] [Abstract] [Full Text] [Related]
15. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
16. Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience.
da Silva Fontinele DR; Assunção Ribeiro da Costa RE; da Silva Magalhães MK; Vieira SC
Breast Dis; 2022; 41(1):249-254. PubMed ID: 35570472
[TBL] [Abstract] [Full Text] [Related]
17. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and palb2 in a Tumor-Only Genomic Testing Program.
Bychkovsky BL; Li T; Sotelo J; Tayob N; Mercado J; Gomy I; Chittenden A; Kane S; Stokes S; Hughes ME; Kim JS; Umeton R; Awad MM; Konstantinopoulos PA; Yurgelun MB; Wolpin BM; Taplin ME; Newmark RE; Johnson BE; Lindeman NI; MacConaill LE; Garber JE; Lin NU
Clin Cancer Res; 2022 Jun; 28(11):2349-2360. PubMed ID: 35363308
[TBL] [Abstract] [Full Text] [Related]
18. pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
19. PARP Inhibitors in pancreatic cancer.
Brown TJ; Reiss KA
Cancer J; 2021 Nov-Dec 01; 27(6):465-475. PubMed ID: 34904809
[TBL] [Abstract] [Full Text] [Related]
20. Germline palb2 Variants and PARP Inhibitors in Endometrial cancer.
Cilento MA; Poplawski NK; Paramasivam S; Thomas DM; Kichenadasse G
J Natl Compr Canc Netw; 2021 Nov; 19(11):1212-1217. PubMed ID: 34781271
[TBL] [Abstract] [Full Text] [Related]
[Next]
